News for Corvus Pharmaceuticals, Inc. (CRVS)

**media[651596]**

Corvus Pharmaceuticals (CRVS) has released interim results from its Phase 1 trial of soquelitinib for moderate to severe atopic dermatitis. This double-blind, p

Corvus Pharmaceuticals (CRVS) is experiencing a significant surge in investor search activity, highlighted by a 324% increase as reported by InvestingChannel. T

China-headquartered ZK International Group Co., Ltd. (ZKIN) is up over 72 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

Shares of Pinterest, Inc. PINS rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter sales results and issued...

Release Date: May 08, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Corvus Pharmaceut

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NCRVS.OQ - Corvus Pharmaceuticals IncQ1 2025 Corvus Pharmaceuticals Inc Earnings CallMay 08, 20

Q1 2025 insights from Corvus Pharmaceuticals highlight promising soquelitinib trial results, extended funding, and plans for Phase 2 trials.

Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper r

Data continue to demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Data to be prese

Corvus Pharmaceuticals (CRVS) will present new interim data from its Phase 1 trial of soquelitinib for atopic dermatitis at the SID 2025 Annual Meeting.

SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. ( CRVS), a clinical-stage biopharmaceutical company, announced to

**media[590863]**

Corvus Pharmaceuticals suffered lately, especially after it announced in December 2024 its early AD data. Check out why I rate CRVS stock as a Hold.

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2024 Earnings Call Transcript March 25, 2025Corvus Pharmaceuticals, Inc. misses on earnings expectations.

Discover Corvus Pharmaceuticals' Q4 2024 earnings insights, highlighting soquelitinib's trial progress, upcoming milestones for 2025, and robust financial...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2024 Earnings Conference Call March 25, 2025 4:30 PM ETCompany ParticipantsZack Kubow - Real Chemistry, IRLeiv...

**media[576504]**

Data to be presented in oral session and poster at the 16th Annual T-Cell Lymphoma Forum SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Cor